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Abstract As scientific techniques for the detection of cyto-
megalovirus (CMV) improve, we are able to detect small
amounts of CMV in the mucosal wall. As clinicians, we are
unsure how to interpret the results of this novel test. There is
controversy in the literature as to the significance of the
detection of CMV in the gut. Whilst the importance of CMV
and reactivation of the virus is clear in those patients such as
allograft recipients with established immune compromise, the
role is less clear in patients with less damaged immune sys-
tems. We explore whether the detection of CMVin such cases
influences outcome and how it should be optimally managed.
We discuss the optimal management of such cases, according
to current guidelines, with a review of the literature.
Introduction
In the apparently immunocompetent patient presenting with
bloody diarrhoea for the first time, there is often diagnostic
uncertainty as to whether the cause of colitis is likely to be
infectious or inflammatory. Risk factors for an infectious
aetiology include undiagnosed immune compromise [such
as human immunodeficiency virus (HIV)], travel, exposure
to antibiotics or hospital, and unprotected sexual intercourse.
Even when an infectious colitis is diagnosed, this does not
exclude the possibility ofa subsequentdiagnosis ofaninflam-
matory bowel disease, which may present initially as an
infective colitis. In a first episode of severe colitis which fails
to respond to steroids or other immunosuppressive therapy,
guidelines suggest that we should look for cytomegalovirus
(CMV) at sigmoidoscopy [1]; however it is acknowledged
that the subsequent detection of CMV can be difficult to
interpret. The diagnosis of CMV colitis in the immunocom-
petent host is rare, but needs to be considered, alongside the
possibilityofundiagnosed immunocompromise,inthe patient
that fails to respond to maximal immunosuppressive therapy.
Case reports and case series of immunocompetent patients
with CMV colitis have been published; however, the patients
included often had comorbidities or pregnancy, which could
affect their immune status [2]. Although CMV may be detect-
ed at diagnosis in an immunocompetent patient with ulcera-
tive colitis, it is more commonly diagnosed following immu-
nosuppressive treatment for colitis. The literature regarding
the importance of the positive CMV result on biopsy is
reviewed here with respect to the following questions:
Is CMVever the sole cause of colitis in an immunocompetent
host?
CMV is a major cause of morbidity in immunosuppressed
patients, causing significant disease in transplant patients and,
prior to the introduction of highly active antiretroviral therapy
(HAART), in HIV. In such patients, end-organ involvement
following viraemic spread of CMV may lead to damage to a
singleorgan, as seen in, for example, colitis, retinitis or severe
pneumonitis.CMVisalsoknownashumanherpesvirus5and,
likeotherherpesviruses,itcausesaprimaryinfectionfollowed
by the establishment of latency, a dormant infection in which
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the virus reactivates due to perturbations in immunity, e.g. as
seenwithageorimmunosuppressivedrugs.CMViscommon,
with a seroprevalence (CMV IgG-positive) of 40–100 % in
adults, increasing with age [3]. Primary infection is often
asymptomatic in the immunocompetent host but can cause a
mild febrile illness and an infectious mononucleosis syn-
drome. However, single-organ pathology, such as hepatitis,
retinitis or colitis, occurs rarely following primary infection or
reactivation in an immunocompetent host [4].
CMV colitis in the immunocompetent patient is uncom-
mon, though it has been described as presenting with a syn-
drome incorporating symptoms of colitis (e.g. abdominal
pain, fever, diarrhoea, rectal bleeding). Galiatsatos et al.
reviewed the literature and found 44 immunocompetent pa-
tients with CMV colitis; however, 34 of these patients had
comorbidities that would be expected to affect immune func-
tion (pregnancy, renal disease, diabetes, malignancy) [2]. In
thatstudy,ageover55yearswas foundtobeassociatedwitha
poor outcome. This small study suggested that the diagnosis
in an immunocompetent patient is rare and raises the question
of either an alternative diagnosis, such as a new presentation
of inflammatory bowel disease (IBD), or a previously unde-
tected immune deficiency (such as HIV). Even mild immu-
nosuppression, as seen in chronic kidney disease, seems to
predispose to CMVreactivation and colitis [5]. Therefore, the
answer to this question is probably yes, but rarely.
How can we diagnose CMV colitis?
Although a wide range of diagnostic tests for CMV is avail-
able, each has limitations (Table 1). Serology is useful to
establish evidence of previous infection (CMV IgG) and IgG
avidity can help to estimate the time of primary infection, as
the IgM antibody can remain positive for up to a year follow-
ing primary infection.
If CMV colitis is suspected, the bowel is examined endo-
scopicallyforevidenceofCMVdisease.Thismaybedetected
as typical findings on histology, such as owl’s eye inclusion
bodies. This histologicalappearanceisveryspecificfor CMV,
has a clear relation to polymerase chain reaction (PCR)
detection of CMV in the gut [6] and provides the mainstay
of diagnosing CMV end-organ disease post-transplant [7].
However, histology has a low sensitivity, so CMV infection
may be missed. Immunohistochemistry (IHC) or simple
haematoxylin and eosin (H&E) staining can be used to im-
prove sensitivity if a diagnosis of CMV colitis is considered
(Fig. 1). Histology, H&E and IHC stains retain specificity for
CMV disease. CMV DNA detection in the blood by PCR has
replaced the previous technique of CMV pp65 antigen detec-
tion and high levels of CMV DNA in the blood correlate with
positive IHC and detection in tissue [8]. However, 15 % of
people with end-organ damage causing retinitis were found to
havenoCMVdetectableintheirbloodinthepre-HAARTera,
suggesting that viraemia does not always persist until the time
of clinical presentation [9]. Modern studies suggest that CMV
PCRinstool may, indue course, allow ustodetectCMV with
an o n - i n v a s i v et e s t[ 10]. Unfortunately, currently, the most
sensitive test for CMV, CMV biopsy PCR, does not seem to
havesufficientspecificitytobeusedalonetomakeadiagnosis
of CMV colitis. CMV viral cell culture is also sensitive but
labour-intensive and has, therefore, been replaced by nucleic
acid detection. As these tests detect CMVat very low levels,
they also detect small amounts of reactivating virus that may
not be causing disease. In the immunocompetent host, peri-
odic reactivation of CMV does not necessarily indicate pa-
thology. The significance of such small amounts of CMV in
the colon has not been established. Lawlor and Moss found
that the majority of published studies detected CMV DNA in
the bowel in a significant proportion of patients without
detection by H&E or IHC [11]. They suggest that the use of
a ‘cut-off’ DNA level might aid diagnosis where CMVin the
colon could be considered important only when present at
above a certain level. That level has not yet been established
and further work is clearly needed in this area.
Does the presence of CMV correlate with disease activity?
CMV has been found in approximately a third of samples
from patients with severe ulcerative colitis [12]. In contrast, in
inactive colitis, the detection of CMV DNA is rare [13].
Although CMV DNA is detected more often in severe colitis,
Table 1 Summary of diagnostic tests for cytomegalovirus (CMV)
IgG IgM Avidity Blood detection
CMV (DNA)
Virus culture from
urine or throat
Immunohistochemistry Histology CMV DNA on
biopsy
Active infection + +/− High/Low + + + +/− +
Infection within last 2–4m o n t h s + + L o w + / − +/− +/− +/− +/−
Infection within last 4–24 months + +/− High +/− +/− +/− +/− +/−
Inactive Infection + − High −− − − −
Reactivation + + High +/− +/− +/− +/− +/−
Reexposure + + High +/− +/− +/− +/− +/−
14 Eur J Clin Microbiol Infect Dis (2015) 34:13–18it is unclear whether it is a causative factor. Alternatively, the
CMV DNA may be detected because of inflammation and
loss of integrity of the bowel wall. Local inflammation in the
bowel wall leads to the release of cytokines such as TNF-α
and IFN-γ. These cytokines may activate CMV replication
and promote the migration of CMV-infected macrophages to
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Fig. 1 a and b show endoscopic
appearances of the proximal
ascending colon in our patient. c
shows her histology and d shows
histology from a patient with
cytomegalovirus (CMV) colitis
and typical owl’s eye inclusion
Fig. 2 Proposed cycle of
pathology
Eur J Clin Microbiol Infect Dis (2015) 34:13–18 15inflamed tissue to further propagate infection (Fig. 2)
[14]. If CMV was a significant factor in pathology, one
would expect those patients with IBD and positive
CMV IgG to have a worse outlook than patients with
negative CMV IgG, but in a study of 187 patients, the
twogroupswerefoundtohavesimilarappearances ofmucosa
at colonoscopy [15]. In addition, the presence of CMV DNA
in blood does not seem to predict the deterioration of IBD in
prospective studies.
Is CMVa precipitant for IBD?
Although the detection of CMV has been found to be associ-
ated with severe disease in IBD, there is no evidence that this
relationship is causative. CMV at presentation of ulcerative
colitis or IBD does occur, but is rare. Blood PCR is often
positive after 2–3 weeks of steroid treatment but this rarely
leads to CMV disease on histology with DNA levels lower
than those seen in transplant patients and CMV DNA levels
falling as steroids are reduced [16]. In transplant patients, the
administration of steroids reduces the CMV viral load re-
quired to cause end-organ disease and perhaps this interaction
also occurs in the immunocompetent patient [17].
Does the presence of CMV simply reflect the degree
of immunosuppression?
CMV is detected more often in cases of steroid-refractory
disease [13]. It is unclear if such patients would have more
CMV because they have more inflammation or because they
havereceivedgreaterdosesofimmunosuppressioninaneffort
to control their colitis. In some patients, CMV detection
occurs prior to the prescription of immunosuppressants, but
in IBD, CMV is commonly detected following immunosup-
pressant therapy. Matsuoka et al. demonstrated a worse prog-
nosis in those with high levels of CMV in blood leading to
greater requirements for ciclosporin [16]. In turn, patients
treated with ciclosporin also develop more CMVand have a
poorer prognosis [18]. Studies in organ transplant recipients
have shown that higher levels of immunosuppression lead to
Fig. 3 Flow chart of suggested management
16 Eur J Clin Microbiol Infect Dis (2015) 34:13–18higher rates of CMV disease. Extrapolated to IBD, this sug-
gests that more CMV may be seen when more immunosup-
pressants are used [19]. In the case of the detection of CMV
DNA in the mucosal wall in the presence of colitis, it is
usually unclear whether the CMV is the cause of pathology
or an innocent bystander.
Can treating CMV improve outcome in patients with colitis?
Although guidelines are universal in recommending the treat-
ment of CMVin severe refractory colitis with CMV detected,
this guidance is based on a number of small studies with
inconclusive outcomes. A randomised controlled study in
HIV in the pre-HAART era showed a benefit of treating
CMV colitis in acquired immunodeficiency syndrome
(AIDS) [20], but no randomised controlled studies have been
done in immunocompetent hosts. Those retrospective studies
or observational studies performed in immunocompetent
hosts are confounded, as treatment with ganciclovir is more
often used in patients with more severe disease. It is known
that, in the absence of anti-CMV treatment in colitis,
reactivated CMV may resolve spontaneously [16]. CMV
viraemia post-transplant also frequently resolves without spe-
cific anti-CMV treatment [21]. There are insufficient pub-
lished data to determine if treating CMV impacts upon major
outcomes such as colectomy rates and mortality [11].
How should we manage a patient with CMV detected
on colonic biopsy?
The American College of Gastroenterology (ACG) and the
European Crohn’s and Colitis Organization (ECCO) recom-
mend treatment of CMV with antivirals only when a patient
with severe colitis is failing to respond to immunosuppressive
therapy [1, 3]. The ECCO state that, when detected only by
PCR, in the absence of supportive histology or immunohisto-
chemistry, the detection of CMV may not always suggest
disease. They recommend the discontinuation of immunosup-
pressiveagentsonlyincasesofseverecolitiswithdetectionof
CMV in the mucosa but do not state clearly in what form the
detection may occur. The British Society of Gastroenterology
(BSG) refers to the ECCO guidance but consider the situation
in greater detail. They describe the situation in which active
CMV colitis in a patient on immunosuppression is difficult to
distinguish from a flare of IBD. They suggest treatment of
CMVand discontinuation of immunomodulators in severe or
refractory colitis in which CMV is detected by histology and
PCR [22]. Our proposed flow chart (Fig. 3) illustrates the
British approach to management. However, these guidelines
may be outdated as more recent data suggest that early detec-
tion and treatment of CMV may be beneficial. Roblin et al.
found that a CMV DNA load above 250 copies/mg in tissue
was predictive of resistance to three successive treatment
regimens for ulcerative colitis and suggest that it might be
prudent to treat those patients found to have high CMV DNA
levels before they deteriorate [23].
Summary
The current position with respect to the detection of CMV in
the bowel mucosa in colitis is unclear. This is particularly
important in the patient with severe colitis on immunosup-
pression and detection of CMV. The risks and benefits of
reducing immunosuppression and prescribing treatment for
CMVin such a patient are not determined. There is an urgent
need for further work in this field. Studies are needed in order
to clearly define the significance of a positive CMV in the
bowel (or stool) in colitis; to determine if patients with CMV
detected by PCR, but not biopsy-proven, would benefit from
antiviral treatment; and to determine whether reduction in
immunosuppression causes more harm than good in such
patients.
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